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‘‘All true universities, whether public or
private, are public trusts designed to advance
knowledge by safeguarding the free inquiry of
impartial teachers and scholars. Their
independence is essential because the
university provides knowledge not only to its
students, but also to the public agency in need
of expert guidance and the general society in
need of greater knowledge;... these latter
clients have a stake in disinterested
professional opinion, stated without fear or
favor, which the institution is morally
required to respect.’’ — American Association
of University Professors [1]
Public skepticism about the timeliness,
accuracy, and completeness of
reporting clinical trial results has never
been more pervasive. The topic
continues to attract attention from the
media and the United States Congress
[2,3]. Recent allegations that have
shaken public conﬁdence include
suppression of studies of
antidepressants in adolescents that
failed to show effectiveness [4] and
failure to describe adequately the
cardiovascular risks of some COX-2
inhibitors, most notably Vioxx
(rofecoxib) [5]. Because such clinical
trials often involve participation by
medical schools, teaching hospitals, and
prominent faculty frequently sought
after by industry as ‘‘thought leaders,’’
this climate of unease and mistrust
severely challenges the integrity of
academic medicine as well as that of
biopharmaceutical sponsors.
Some sectors of the international
clinical trials enterprise have begun to
respond to the gathering crisis of
conﬁdence. The editors of major medical
journals, particularly the members of the
International Committee of Medical
Journal Editors (ICMJE), have
promulgated strong positions on
authorship [6] and mandatory ‘‘full’’
registration of clinical trials in publicly
funded, freely accessible registries [7,8].
The National Institutes of Health (NIH)
has established the sole publicly funded
and operated clinical trials registry in the
United States, accessible at http://www.
clinicaltrials.gov [9]. The World Health
Organization (WHO) has deﬁned a
‘‘minimum dataset’’ for clinical trials
registration and continues to negotiate
the details of its universal adoption by
industry [10,11]. Comprehensive
legislation (the Fair Access to Clinical
Trials Act of 2005 [12] and the American
Center for Cures Act of 2005 [13]) has
been introduced in the United States
Congress. The Public Library of Science
(PLoS) has partnered with the American
Medical Informatics Association to
develop the Global Trial Bank [14], the
ﬁrst independently operated, peer-
reviewed, freely accessible repository for
clinical trial results. PLoS’ newest open-
access journal, PLoS Clinical Trials, is
committed to publishing the results of
ethically and scientiﬁcally sound clinical
trials without regard to their direction or
perceived importance [15]. These
developments are encouraging,
notwithstanding a continued absence of
consensus about the speciﬁc identifying
information that should be registered for
each clinical trial, the format and detail
with which trial results should be
deposited, and how much of, and at what
point, this information should be publicly
accessible [16].
Not so encouraging is the signiﬁcant
variation across the academic community
in standards that protect the right and
duty of academic investigators to take
appropriate responsibility for the design,
analysis, and reporting of clinical
research, especially clinical trials
sponsored by industry [17,18]. Such
variation is troubling for many reasons,
but two are of cardinal importance. First,
clinical research involving human
participants can only be justiﬁed ethically
when such experiments are done to
produce generalizable knowledge [19,20].
We and others [21] interpret that dictum
to mean that the results of human
experimentation should be made known.
Second, academic medical institutions
and faculty have occupied an especially
privileged place in society as stewards and
trustworthy sources of the independent
and impartial research, accurate
information, and unbiased interpretation
that are necessary for society to make
sound policy choices.
Because inconsistency in research
standards can affront human research
ethics, undermine academic integrity,
distort public policy and medical
practice, and impair public health, the
Association of American Medical Colleges
(AAMC), in collaboration with the
Centers for Education and Research in
Therapeutics and the BlueCross
BlueShield Association, convened in June
2005 a panel of nationally recognized
experts and developed a set of principles
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of broad interest to a general medical audience.for conducting and reporting clinical
research. (See Box 1.) The principles were
endorsed by AAMC’s governance in
September 2005 and have been shared
widely with medical, scientiﬁc, and
patient organizations and with senior
biopharmaceutical executives, with the
goal to identify areas of agreement and
concern among these diverse
stakeholders in clinical research. In
response to these comments, the
document was revised to resolve
ambiguous language and clarify certain
technical requirements, and the ﬁnal
version appeared in January 2006 [22].
The principles express the
fundamental responsibilities of academic
institutions and faculty for research
conducted under their auspices.
Accordingly, they should apply to all
clinical trials conducted in academic
medical institutions, regardless of the
source of funding. They encompass
single-site as well as multisite studies,
although the actual application of the
principles may differ in detail across
study types and sizes. ‘‘Clinical trials’’ are
deﬁned here in accordance with the
ICMJE standards that explicitly exclude
Phase 1 and early (exploratory) Phase 2
studies (but not all late-Phase 2 studies)
and that include all Phase 3 and 4 clinical
trials, including studies of new
indications for approved products [7,8].
Whenever principles of engagement
are promulgated, the challenge is to win
the allegiance of those whose interests are
most at stake. Although the principles
presented here emanate from
fundamental tenets of sound scientiﬁc
scholarship and human research ethics—
and should be applicable, to the extent
appropriate, to all clinical research
involving human participants, regardless
of site or sponsorship—they will
doubtless challenge both academia and
industry. For academic institutions, the
rapid doubling of the NIH budget
spurred major increases in ﬁnancial
investments and indebtedness and
expanded biomedical research capacity.
The recent abrupt ﬂattening of NIH
appropriations [23] makes commercial
funding ever more attractive to
researchers and may tempt academic
institutions to stretch—or ignore—their
policies to appear more accommodating
to industry sponsors.
For the biopharmaceutical industry,
widely publicized concerns about ‘‘dry
pipelines’’ [24], expiring patents that
threaten operating margins, questionable
practices in clinical trials, and plunging
public esteem [25,26] may only intensify
Box 1. Principles for Protecting Integrity in the Conduct and Reporting of
Clinical Trials
These appear verbatim from [22].
Publications and Public Availability of
Research Results
1. Researchers and their institutions have an
ethical obligation when conducting human
research to seek to make the results available
publicly.
2. Contracts between sponsors and institutions
for conducting clinical trials should require a
good faith effort to publish the results of such
trials in a peer reviewed journal in a timely
fashion.
3. Contracts for clinical trials should contain a
commitment of adequate funding to cover the
full costs of the analysis defined in the protocol
and the costs associated with publishing the
results. This principle applies even when the
study is terminated for any reason prior to
meeting its pre-specified objectives.
4. All trials meeting the ICMJE requirements [7,8]
for registration should make their results publicly
available, by means of a link to any peer reviewed
publications and by posting the results in an
online accessible repository, within 18 months of
submission of a manuscript for publication. (The
WHO is leading an international effort to promote
registration ofclinical trials, buthasnotyet gained
consensus on the issue of ‘‘masking’’ of certain
elements in the minimum data set required for
registration. Because of continuing uncertainty,
the WHO effort is acknowledged but not included
as an alternative to the ICMJE registration
requirements.)
5. After publication of the results, the sponsor, the
investigators, andtheirinstitutionsshould adopta
model for public sharing of the data underlying
publications, similar to that of NIH [28], which
permits exceptions for confidential or proprietary
information.
Registration of Clinical Trials
6. Within 21 days of initiating enrollment of
participants, any clinical trial covered by these
principles should be fully registered pursuant to
the ICMJE requirements [7,8] for registration.
Registration must include the assignment of a
unique identifying number to each clinical trial.
7. Registration should be accomplished either in
clinicaltrials.gov or in another public, non-profit,
international registry and should include all of the
elements required by that registry.
8. Insofar as is feasible, trial registration data
should be regularly updated to include a link to all
published reports associated with the study.
Lead Investigator and Steering Committee
9. A multisite clinical trial, at the outset, should
identify a lead or principal investigator and a
steering committee to represent the full body of
investigators.
Publication and Analysis Committee
10. A multisite clinical trial, at the outset, should
establish a publication and analysis committee
[hereinafter P&A committee]. It is essential that
the P&A committee be independent of the
sponsor’s control, have access to the full data
set, understand and implement the prespecified
analysis plan, and have the resources and skills
both to interpret that analysis and perform
additional analysis if required. In order to
prevent any appearance of undue influence by
the sponsor, the P&A committee should contain a
majority of participating, non-sponsor-employed
investigators, with appropriate skills in analysis
and interpretation of clinical trials. The P&A
committee and the steering committee may
have the same membership.
11. The P&A committee in multisite clinical trials
(or the principal investigator ofsingle site studies),
through a qualified expert of its choosing,
preferably a member of that committee, should
have the right to access any data generated
during the study that the committee deems
necessary to ensure the integrity and validity of
the study and its full reporting.
12. The P&A committee in multisite clinical trials
(or the principal investigator in single site studies)
should require that the sponsor of the study
perform its analysis of trial data in a defined
period of time. The committee (or PI) should be
able to conduct its own analysis through an
expert selected by it, to the extent it deems this
necessary. Whenever feasible, the expert should
be agreed upon by the P&A committee and the
sponsor.
13. The sponsor should share with the P&A
committee all analyses called for by the study
that the sponsor conducts of any biological
materialsitreceivesduringthecourseofthestudy.
14. The P&A committee or PI should make a good
faith effort to disseminate the results of the study
through peer reviewed mechanisms.
Individual Publication
15. Site-specific publications in multisite trials
have an unavoidable potential for bias. Because
they are almost never part of the original analytic
plan, they are often misleading, and should be
strongly discouraged. However, to respect an
academic institution’s commitment to academic
freedom,site-specificanalysesshouldnonetheless
be permitted with conditions. Accordingly, an
individual site investigator in a multisite trial
should be free to analyze and publish data from
the individual site, consistent with sound
principles of science and analysis, but only after
review and comment by the P&A committee and
only after publication of the study as a whole, or,
in the absence of acceptance of the full
publication, within 2 years from the specified
end points or earlier termination of the study.
Authorship
16. Ghost or guest authorship is unacceptable.
Authorship implies independent, substantial, and
fullydisclosed participationinthe study andinthe
preparation of the manuscript. It is acceptable for
employees of the sponsor to participate in
drafting and publication activity, but only if their
roles are fully disclosed.
17. Institutions conducting clinical trials should
adopt as policy the standards of authorship
defined by the ICMJE.
18. Where applicable, investigators should use the
CONSORT principles [29,30] as guidance for
publication of trial results.
19.Investigatorsshouldfullydisclose,andjournals
should publish, the existence of all relevant
financial interests, including consultancies of any
investigator, in all communications of trial results.
20. Any manuscript submitted for publication
should accurately disclose the role of each author
in conducting the study and preparing the
manuscript. Such information should also be
disclosed in any public presentation of study
results, to the extent practicable.
21. Manuscripts submitted for publication should
disclose all previous publications involving the
same protocol or database.
22. Manuscripts submitted for publication should
be accompanied by the protocol and pre-
specified analysis plan and all dated
amendments to them, and any deviations to the
pre-specified plan should be identified and
discussed.
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and impatience with academic
bureaucracy, especially in negotiating
clinical trial agreements and navigating
multiplicative institutional review board
evaluations, while other options like
private, for-proﬁt clinical trial sites and
cadres of willing community physicians
beckon.
For academic investigators eager to
participate in industry-sponsored trials to
help create new medical knowledge and
advance their own professional
development and for their healthcare
institutions that ﬁnd hosting such trials
important marketing assets, the
universities’ efforts to protect academic
freedom often lead to protracted
negotiations over the ﬁne language of
clinical trials contracts, and the process
breeds discouragement, cynicism, and
frustration in all parties. And, of course,
the patients who might wish to
participate in the trials are the ultimate
victims of these clashing institutional
interests.
Notwithstanding these formidable
impediments, we are optimistic that the
principles outlined here will be adopted
widely across the professional community
as expressions of long-endorsed values
and practices. We also hope they will be
championed by patients, potential
research participants, and their advocacy
groups, for whom this effort to
strengthen the integrity and credibility of
clinical trials results and the evidentiary
base of medical practice can only be
beneﬁcial.
Both industry and academia have been
punished in the last decade by harsh
publicity and congressional rebukes over
revelations of questionable (or worse)
practices in conducting and reporting
clinical research, hidden ﬁnancial
conﬂicts of interest, and tragic clinical
research mishaps. Both sectors may
welcome the opportunity to reafﬁrm
more conﬁdently that their partnership in
clinical research, so vital for translating
scientiﬁc advancements into better health
care and improved public health, is
‘‘principled, protective of research
subjects, and capable of withstanding
intense public scrutiny’’ [27]. We argue
that the adoption and consistent practice
of these principles will contribute greatly
to that outcome. “
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  There is growing public skepticism about
the accuracy and completeness of reporting
of clinical trial results.
  Academic medical institutions and their
faculty often play leading roles in
performing and reporting clinical trials.
  Clinical research in humans can only be
justified ethically when it leads to
generalizable knowledge, which means
results should be disclosed.
  AAMC has developed principles for
conducting and reporting clinical research
that ensure to investigators full right of
independent access to and analysis of the
underlying data.
  The principles aim to ensure that the
conduct and reporting of clinical research
conform to the highest standards of
scientific and ethical integrity.
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